Prevalence and risk factors for therapy escalation in ulcerative colitis in the Swiss IBD Cohort Study by Safroneeva, Ekaterina et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Prevalence and risk factors for therapy escalation in ulcerative colitis in the
Swiss IBD Cohort Study
Safroneeva, Ekaterina; Vavricka, Stephan R; Fournier, Nicolas; Straumann, Alex; Rogler, Gerhard;
Schoepfer, Alain M
Abstract: BACKGROUND: Physicians traditionally treat ulcerative colitis (UC) using a step-up ap-
proach. Given the paucity of data, we aimed to assess the cumulative probability of UC-related need for
step-up therapy and to identify escalation-associated risk factors. METHODS: Patients with UC enrolled
into the Swiss IBD Cohort Study were analyzed. The following steps from the bottom to the top of the
therapeutic pyramid were examined: (1) 5-aminosalicylic acid and/or rectal corticosteroids, (2) systemic
corticosteroids, (3) immunomodulators (IM) (azathioprine, 6-mercaptopurine, methotrexate), (4) TNF
antagonists, (5) calcineurin inhibitors, and (6) colectomy. RESULTS: Data on 996 patients with UC with
a median disease duration of 9 years were examined. The point estimates of cumulative use of different
treatments at years 1, 5, 10, and 20 after UC diagnosis were 91%, 96%, 96%, and 97%, respectively, for
5-ASA and/or rectal corticosteroids, 63%, 69%, 72%, and 79%, respectively, for systemic corticosteroids,
43%, 57%, 59%, and 64%, respectively, for IM, 15%, 28%, and 35% (up to year 10 only), respectively,
for TNF antagonists, 5%, 9%, 11%, and 12%, respectively, for calcineurin inhibitors, 1%, 5%, 9%, and
18%, respectively, for colectomy. The presence of extraintestinal manifestations and extended disease
location (at least left-sided colitis) were identified as risk factors for step-up in therapy with systemic
corticosteroids, IM, TNF antagonists, calcineurin inhibitors, and surgery. Cigarette smoking at diagnosis
was protective against surgery. CONCLUSIONS: The presence of extraintestinal manifestations, left-
sided colitis, and extensive colitis/pancolitis at the time of diagnosis were associated with use of systemic
corticosteroids, IM, TNF antagonists, calcineurin inhibitors, and colectomy during the disease course.
DOI: 10.1097/MIB.0000000000000368
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-119277
Published Version
Originally published at:
Safroneeva, Ekaterina; Vavricka, Stephan R; Fournier, Nicolas; Straumann, Alex; Rogler, Gerhard;
Schoepfer, Alain M (2015). Prevalence and risk factors for therapy escalation in ulcerative colitis in the
Swiss IBD Cohort Study. Inflammatory Bowel Diseases, 21(6):1348-1358. DOI: 10.1097/MIB.0000000000000368
ORIGINAL ARTICLE
Prevalence and Risk Factors for Therapy Escalation in Ulcerative
Colitis in the Swiss IBD Cohort Study
Ekaterina Safroneeva, PhD,* Stephan R. Vavricka, MD,†,‡ Nicolas Fournier, PhD,§ Alex Straumann, MD,k
Gerhard Rogler, MD, PhD,† and Alain M. Schoepfer, MD¶ on behalf of the Swiss IBD Cohort Study Group
Background: Physicians traditionally treat ulcerative colitis (UC) using a step-up approach. Given the paucity of data, we aimed to assess the
cumulative probability of UC-related need for step-up therapy and to identify escalation-associated risk factors.
Methods: Patients with UC enrolled into the Swiss IBD Cohort Study were analyzed. The following steps from the bottom to the top of the therapeutic
pyramid were examined: (1) 5-aminosalicylic acid and/or rectal corticosteroids, (2) systemic corticosteroids, (3) immunomodulators (IM) (azathioprine,
6-mercaptopurine, methotrexate), (4) TNF antagonists, (5) calcineurin inhibitors, and (6) colectomy.
Results: Data on 996 patients with UC with a median disease duration of 9 years were examined. The point estimates of cumulative use of different
treatments at years 1, 5, 10, and 20 after UC diagnosis were 91%, 96%, 96%, and 97%, respectively, for 5-ASA and/or rectal corticosteroids, 63%, 69%,
72%, and 79%, respectively, for systemic corticosteroids, 43%, 57%, 59%, and 64%, respectively, for IM, 15%, 28%, and 35% (up to year 10 only),
respectively, for TNF antagonists, 5%, 9%, 11%, and 12%, respectively, for calcineurin inhibitors, 1%, 5%, 9%, and 18%, respectively, for colectomy. The
presence of extraintestinal manifestations and extended disease location (at least left-sided colitis) were identiﬁed as risk factors for step-up in therapy with
systemic corticosteroids, IM, TNF antagonists, calcineurin inhibitors, and surgery. Cigarette smoking at diagnosis was protective against surgery.
Conclusions: The presence of extraintestinal manifestations, left-sided colitis, and extensive colitis/pancolitis at the time of diagnosis were associated
with use of systemic corticosteroids, IM, TNF antagonists, calcineurin inhibitors, and colectomy during the disease course.
(Inﬂamm Bowel Dis 2015;21:1348–1358)
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U lcerative colitis (UC) is a chronic inﬂammatory disorder of thecolorectum of unknown etiology. It is believed that UC
develops due to a dysregulated mucosal immune response to
commensal gut ﬂora in genetically susceptible individuals.1 The
risk of UC is the highest in North America and northern Europe
with incidence rates varying from 9 to 20 cases per 100,000 person-
years and prevalence rates from 156 to 291 cases per 100,000
inhabitants.1 Traditionally, physicians treat patients with UC using
a step-up approach. Newly diagnosed individuals with mild-to-
moderate UC are usually ﬁrst treated with 5-aminosalicylic acid
(5-ASA), which is considered to be an effective and inexpensive
treatment that provides rapid symptom relief.2,3 In case of insufﬁ-
cient response or intolerance to 5-ASA, patients may require
corticosteroids and/or immunomodulators, such as azathioprine or
6-mercaptopurine, as a step-up therapy.4,5 In case of insufﬁcient
response to corticosteroids and/or immunomodulators, therapeutic
options, such as inﬂiximab, adalimumab, cyclosporine, or tacroli-
mus, may be necessary.6,7 In case of a failure of all pharmacologic
therapies, a (procto)colectomy can be performed.
Although several studies have evaluated the cumulative
probability of surgery over time, the studies that have systemat-
ically analyzed the risk factors associated with the need for
therapeutic escalation in patients with UC are rare.8–11 The knowl-
edge of such risk factors may assist physicians in choosing the
appropriate therapy for a given patient with UC depending on his/
her risk proﬁle.
In this study, we aimed to assess the cumulative probability
of UC-related need for step-up in therapy over time and to identify
speciﬁc risk factors associated with a therapy escalation.
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MATERIALS AND METHODS
Patients
Starting in 2006, patients with IBD from all regions of
Switzerland have been included into the Swiss Inﬂammatory
Bowel Disease Cohort Study (SIBDCS). The SIBDCS is
supported by a research grant from the Swiss National Science
Foundation and approved by the local ethics committees. The
cohort proﬁle has been described by Pittet et al.12 To be included
into the study, patients signed written informed consent. Perma-
nent residency status in Switzerland and/or coverage by a Swiss
health insurance plan were mandatory requirements for inclusion
of patients. Upon inclusion, patients undergo a thorough clinical
and laboratory assessment. Patients attend follow-up visits at least
once a year. The enrollment and follow-up questionnaires capture
clinical, socioeconomic, and psychosocial data. Detailed question-
naires designed to assess physician-determined measures are
completed by the treating physicians, whereas questionnaires de-
signed to assess patient-reported outcomes, such as quality of life,
social impairment, and symptoms, are completed by patients with
IBD themselves. The data from questionnaires of all patients
included into the SIBDCS between November 2006 and June
2013 were used for the analysis performed in this article. Patients
included in this study were recruited in the following health care
settings: 61% at university hospitals, 13% at large nonuniversity
hospitals, 6% at county hospitals, and 20% in private practice. In
Switzerland, family physicians serve as primary care providers. If
IBD is suspected, patients are then referred by family physicians
to gastroenterologists.
Methods
The data obtained from questionnaires completed by
patients and physicians were collected and validated by the staff
at the SIBDCS data center. Rigorous rules were followed to
ensure data quality. The prescription of the following therapies
was analyzed over time: topical 5-ASA, oral 5-ASA, rectal
budesonide (enema or foam), systemic corticosteroids (oral
budesonide and prednisone), azathioprine, 6-mercaptopurin,
methotrexate, inﬂiximab, adalimumab, certolizumab pegol, cyclo-
sporine, and tacrolimus.
We deﬁned the following steps in the step-up approach to
UC treatment: (1) use of 5-ASA (administered either topically
[suppositories, enema] and/or orally) or rectal corticosteroids
(budesonide enema or foam) or both, (2) use of systemic cortico-
steroids (oral budesonide or prednisone or equivalent drugs), (3)
use of immunomodulators (azathioprine, 6-mercaptopurine, meth-
otrexate), (4) use of TNF antagonists (inﬂiximab or adalimumab),
(5) use of calcineurin inhibitors (cyclosporine, tacrolimus), (6)
undergoing UC-related surgery, which includes proctocolectomy
and colectomy with ileorectal anastomosis.
Of note, inﬂiximab was the only registered anti-TNF therapy
for UC treatment until the company producing adalimumab
obtained regulatory approval for use of this product in Switzerland
in December 2013. Disease activity at inclusion into the SIBDCS
was assessed using the modiﬁed Truelove and Witts activity
index.13 A positive IBD family history was deﬁned as having at
least 1 ﬁrst-degree relative with either UC or Crohn’s disease.
Statistical Analysis
Clinical data were retrieved at the SIBDCS data center
(institut universitaire de médecine sociale et préventive, Univer-
sity of Lausanne). All standard statistical analyses were performed
using Stata (version 12.1; College Station, TX), whereas time-to-
event analyses were performed using the R (version 2.15.1).14
Continuous data distribution was analyzed using Normal
QQ-plots. For continuous data, results were presented as median,
interquartile range and range in case data followed nonnormal
distribution, and as mean 6 SD and range in case of data that
followed normal distribution. For categorical data, results were
presented as absolute numbers and relative frequencies.
TABLE 1. Characteristics of the UC Population
Item Frequency
Sex
Male 539 (54.1%)
Female 457 (45.9%)
Age at inclusion into the SIBDCS (median,
IQR, range)
41, 32–52, 17–84
Age at the time of ﬁrst symptoms related to UC
(median, IQR, range)
31, 23–40, 3–79
Diagnostic delay (median, IQR, range), mo 3, 1–6, 0–194
Disease duration (median, IQR, range), yrs 9, 4–16, 0–49
Disease location at the time of diagnosis
Proctitis 189 (19.0%)
Left-sided colitis 239 (33.0%)
Pancolitis 381 (38.3%)
Unknown/unclear 97 (9.7%)
Disease severity at the time of enrollment
(MTWAI) (median, IQR, range)
3, 1–5, 0–19
Smoking status at the time of diagnosis
Smoker 166 (18.4%)
Nonsmoker 736 (81.6%)
Family history of IBD
Positive history 101 (11.1%)
No history 806 (88.9%)
EIM from the time of enrollment into
SIBDCS (any)
403 (40.5%)
Peripheral arthritis/arthralgia 295 (29.6%)
Uveitis/iritis 56 (5.6%)
Pyoderma gangrenosum 18 (1.8%)
Erythema nodosum 34 (3.4%)
Oral aphthous ulcers 43 (4.3%)
Ankylosing spondylitis 34 (3.4%)
Primary sclerosing cholangitis 39 (3.9%)
IQR, interquartile range; MTWAI, modiﬁed Truelove and Witts activity index.13
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The Kaplan–Meier method was used to examine cumula-
tive proportions of therapy use over time; the Turnbull’s15 exten-
sion to Kaplan–Meier method was used for left-censored data.15
Logistic regression was used to identify factors associated with
the following binary outcomes: use of at least systemic cortico-
steroids (use of systemic corticosteroids or IM or TNF antagonists
or calcineurin inhibitors or surgery) versus no therapy or use of
5-ASA and/or rectal corticosteroids only; use of at least IM (use
of IM or TNF antagonists or calcineurin inhibitors or surgery)
versus no therapy or 5-ASA therapy and/or rectal corticosteroids
or systemic corticosteroids; use of at least TNF antagonists (use of
TNF antagonists or calcineurin inhibitors or surgery) versus no
therapy or 5-ASA and/or rectal corticosteroids or systemic corti-
costeroids or IM; use of at least calcineurin inhibitors (use of
calcineurin inhibitors or surgery) versus no therapy or 5-ASA
and/or rectal corticosteroids or systemic corticosteroids or IM or
TNF antagonists; undergoing UC-related surgery versus no ther-
apy or all pharmacologic therapies. Results were presented as
odds ratio (OR) and 95% conﬁdence interval (CI). Factors with
a P value ,0.1 were entered into a multivariable logistic regres-
sion model. A P value ,0.05 was considered as statistically
signiﬁcant.
RESULTS
Characteristics of the Study Population
The characteristics of the study population are shown in Table 1.
A total of 996 patients with UC were included. Median age at the time
of inclusion into the SIBDCS was 41 years (interquartile range, 32–
52). The disease location at the time of diagnosis was as follows:
proctitis in 189 patients (19.0%), left-sided colitis in 239 patients
(33.0%), extensive colitis/pancolitis in 381 patients (38.3%), and
unknown in 97 patients (9.7%). Median disease duration was 9 (4–
16) years. A total of 403 (40.5%) patients presented with extraintes-
tinal manifestations (EIM) (evaluated from the time of enrollment into
the SIBDCS until the time of last follow-up visit). Colectomy was
performed in 94 patients with UC. Of these, 8 patients (8.5%) suffered
from colorectal cancer and 7 (7.4%) from colonic dysplasia. Seventy-
nine patients with UC (84%) underwent colectomy due to refractory
disease not responding to medication regimens.
Cumulative Proportion of UC-related Drug
Use and UC-related Surgery
Figures 1–4 illustrate the cumulative probability of use of
the different medications and undergoing UC-related surgery for
FIGURE 1. Cumulative probability for the use of 5-ASA and/or rectal corticosteroids, systemic corticosteroids, immunomodulators, TNF antago-
nists, calcineurin inhibitors, and for undergoing surgery for patients with all UC locations examined together.
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all disease locations (Fig. 1), proctitis only (Fig. 2), left-sided
colitis only (Fig. 3), and extensive/pancolitis only (Fig. 4).
In Table 2, the point estimates of cumulative probability of
UC-speciﬁc medication use/undergoing surgery at years 1, 5, 10,
and 20 after UC diagnosis stratiﬁed according to disease location
are shown. Our data indicate that more extensive UC at the time
of diagnosis was associated with a higher probability of treatment
with corticosteroids, TNF antagonists, calcineurin inhibitors, and
undergoing UC-related surgery.
Systematic Analysis of Risk Factors for
Therapy Escalation
We further evaluated which factors might be associated
with therapy escalation using logistic regression modeling. The
following outcomes were analyzed: sex, age at the time of
diagnosis, smoking status at the time of diagnosis, IBD family
history, the presence of EIM from the time of enrollment into the
SIBDCS, disease location at the time of diagnosis, and disease
duration (OR per year of disease duration are shown). The results
of this analysis are illustrated in Table 3. The following factors
were found to be positively associated with the use of at least
systemic corticosteroids during the disease course in the univar-
iate model (Table 3): the presence of EIM (OR ¼ 2.556, P ¼
0.001), left-sided colitis at the time of diagnosis (OR ¼ 2.207,
P , 0.001), and extensive/pancolitis at the time of diagnosis
(OR ¼ 6.064, P , 0.001). We observed a trend for the positive
association between disease duration (per year) and the use of at
least systemic corticosteroids (OR ¼ 1.021, P ¼ 0.057). In the
multivariate model (Table 4), the following factors were signiﬁ-
cantly associated with at least systemic corticosteroid use: the
presence of EIM (OR ¼ 2.393, P , 0.001), left-sided colitis at
the time of diagnosis (OR ¼ 2.211, P , 0.001), and pancolitis at
the time of diagnosis (OR ¼ 5.806, P , 0.001).
We identiﬁed the following factors to be associated with the
use of at least immunomodulators during disease course (Table 3):
age at diagnosis .40 years (OR ¼ 0.728, P ¼ 0.043), the pres-
ence of EIM (OR ¼ 2.110, P , 0.001), left-sided colitis (OR ¼
2.396, P , 0.001), and pancolitis/extensive colitis (OR ¼ 3.768,
P , 0.001) at the time of diagnosis, and disease duration (OR ¼
0.998, P , 0.001). In the multivariate model (Table 4), the fol-
lowing factors were associated with at least IM use: age .40
years at diagnosis (OR 0.706, P ¼ 0.034), the presence of EIM
FIGURE 2. Cumulative probability for use of 5-ASA and/or rectal corticosteroids, systemic corticosteroids, immunomodulators, TNF antagonists,
calcineurin inhibitors, and for undergoing surgery for patients with ulcerative proctitis.
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(OR ¼ 2.048, P , 0.001), left-sided colitis (OR ¼ 2.422, P ,
0.001), and extensive/pancolitis (OR ¼ 3.678, P , 0.001) at the
time of diagnosis.
The following factors were found to be positively associated
with the use of at least TNF antagonists during the disease course
(Table 3): the presence of EIM (OR¼ 2.153, P, 0.001), left-sided
colitis at the time of diagnosis (OR ¼ 2.280, P , 0.001), and
extensive/pancolitis at the time of diagnosis (OR ¼ 3.301, P ,
0.001). The following factors were protective for the use of at least
TNF antagonists: female sex (OR ¼ 0.715, P ¼ 0.019) and older
than 40 years at the time of UC diagnosis (OR ¼ 0.662, P ¼
0.014). In the multivariate model (Table 4), the following factors
were associated with at least TNF-antagonist use: female sex
(OR ¼ 0.723, P ¼ 0.032) older than 40 years at diagnosis
(OR ¼ 0.607, P ¼ 0.004), the presence of EIM (OR ¼ 2.145,
P , 0.001), left-sided colitis (OR ¼ 2.143, P ¼ 0.001), and exten-
sive/pancolitis at the time of diagnosis (OR ¼ 2.903, P , 0.001).
We identiﬁed the following factors to be positively
associated with the use of at least calcineurin inhibitors during
disease course (Table 3): the presence of EIM (OR ¼ 2.343, P ,
0.001) and extensive/pancolitis at the time of diagnosis (OR ¼
2.687, P , 0.001). Because of the limited number of patients
treated with calcineurin inhibitors, no multivariate logistic regres-
sion modeling was performed.
The following factors were found to be positively associ-
ated with patients undergoing at least UC-related surgery in the
univariate model (Table 3): positive family history for IBD (OR ¼
1.877, P ¼ 0.042), presence of EIM (OR ¼ 2.341, P , 0.001),
extensive/pancolitis at diagnosis (OR ¼ 3.898, P , 0.001), and
disease duration (OR ¼ 1.037, P ¼ 0.002). Smoking at the time of
UC diagnosis had a protective effect on UC-related surgery
(OR ¼ 0.336, P ¼ 0.021). The following factors were signiﬁ-
cantly associated with at least UC-related surgery in the multivar-
iate model (Table 4): smoking at the time of diagnosis (OR ¼
0.272, P ¼ 0.008), the presence of EIM (OR ¼ 2.29, P ¼ 0.002),
extensive/pancolitis at diagnosis (OR ¼ 3.083, P ¼ 0.009), and
disease duration (OR ¼ 1.042, P ¼ 0.004).
DISCUSSION
In this study, we assessed the cumulative probability of
patients undergoing therapy escalation in a large cohort of patients
with UC and systematically analyzed risk factors associated with
such a therapy escalation.
FIGURE 3. Cumulative probability for use of 5-ASA and/or rectal corticosteroids, systemic corticosteroids, immunomodulators, TNF antagonists,
calcineurin inhibitors, and for undergoing surgery for patients with left-sided colitis.
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In accordance with the current European Crohn’s and
Colitis Organization guidelines on UC management, the propor-
tion of patients using topical and/or oral 5-ASA products in our
cohort was high.16 We observed that, at year 1 after diagnosis,
91% of all patients with UC use 5-ASA products irrespective of
disease location at the time of diagnosis. When all disease loca-
tions were examined together, the use of 5-ASA products in our
cohort increased from the 91% at year 1 to 96% (95% CI,
94%–97%) at year 10 after UC diagnosis. Given the fact that
rectal budesonide therapy is used mainly in patients with UC with
mild disease, we analyzed rectal steroid use over time together
with 5-ASA drugs.
For all disease locations, the cumulative probability of
systemic corticosteroid use was 63% (95% CI, 59%–65%) at year
1 and 69% (95% CI, 66%–72%) at year 5 after UC diagnosis. In
our cohort, the cumulative probability of corticosteroid use at year
1 after UC diagnosis is higher compared with the 34% (63 out of
185 patients) reported by Faubion et al17 in a population-based
study of patients with UC. The observed difference may be related
to the fact that the SIBDCS is not population-based, and that the
majority of patients (80%) are recruited in a hospital setting,
which may be associated with the inclusion of more severe
patients that are more frequently treated with corticosteroids. A
much lower frequency of corticosteroid use was reported by
Charpentier et al in a population-based cohort (EPIMAD registry)
of 474 patients with UC with disease onset of .60 years of age.
Authors reported that a cumulative probability of corticosteroid
use of 21% (95% CI, 17%–25%) at year 1 after UC diagnosis and
34% (95% CI, 29%–38%) at year 5 after UC diagnosis were
observed.11 In addition, the authors found that elderly onset
IBD is characterized by a milder disease course when compared
with young-onset IBD.11 As such, the difference between the rate
of corticosteroids used in our cohort and in the EPIMAD registry
can be explained by the fact that the EPIMAD registry is
population-based and includes a higher proportion of patients
recruited in private practice, when compared with the SIBDCS,
as well as by a relatively mild disease course in the patients with
elderly onset IBD. Lakatos et al18 reported that 30.4% of patients
with UC (67/220) in a Hungarian incidence cohort used cortico-
steroids over a median follow-up of 5 years, which is much lower
than the 69% (95% CI, 66%–72%) of corticosteroid use that we
observed at 5 years in the SIBDCS. However, the 5-year cumu-
lative probability of corticosteroid use in our cohort is comparable
with the rates observed in patients with Crohn’s disease in
FIGURE 4. Cumulative probability for use of 5-ASA and/or rectal corticosteroids, systemic corticosteroids, immunomodulators, TNF antagonists,
calcineurin inhibitors, and for undergoing surgery for patients with extensive colitis and pancolitis.
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a population-based cohort from Cardiff and regional cohort from
Copenhagen. In these cohorts, the rates of corticosteroid use reach
almost 75% at 5 years after diagnosis.19,20 We could not identify
studies reporting on the cumulative probability of corticosteroid
use at years 10 and 20 after diagnosis in other populations of
patients with UC.
The point estimates of cumulative probability of immuno-
modulator use for all disease locations together were as follows:
43% (95% CI, 40%–46%) at year 1 after diagnosis, 57% (95% CI,
54%–60%) at year 5 after diagnosis, and 59% (95% CI, 55%–
62%) at year 10 after diagnosis. The point estimates of cumulative
probability of immunomodulator use in our cohort are again higher
when compared with those reported by Charpentier et al. Authors
found a cumulative probability of immunomodulator use of
3% (95% CI, 1%–4%) at year 1 after diagnosis, 10% (95% CI,
7%–14%) at year 5 after diagnosis, and 15% (95% CI, 11%–20%)
at year 10 after diagnosis in elderly onset UC patients. Lakatos
et al reported on azathioprine exposure of only 5.9% in an inci-
dence cohort of 220 Hungarian patients with UC with a median
follow-up of 5 years.
For all disease locations together, the point estimates of
cumulative probability of TNF antagonist use were as follows: 15%
(95% CI, 12%–17%) at year 1 after diagnosis, 28% (95% CI, 24%–
32%) at year 5 after diagnosis, and 35% (95% CI, 30%–40%) at
year 10 after diagnosis. Because regulatory approval for adalimu-
mab use in patients with UC in Switzerland was obtained in
December 2013, the majority of patients with UC in this study
were treated with inﬂiximab and only a small fraction with adali-
mumab, which was prescribed after loss of response to inﬂiximab.
Charpentier et al documented a cumulative probability of TNF
antagonist use of 0% at year 1, 0.4% (95% CI, 0.1%–0.6%) at year
5, and 25% (95% CI, 1%–3%) at year 10 after UC diagnosis. We
did not identify other cohort studies in which the cumulative prob-
abilities of anti-TNF treatment over time were examined.
TABLE 2. Proportion of Patients Treated with Various UC-speciﬁc Therapies and/or Undergoing Surgery at Years
1, 5, 10, and 20 After UC Diagnosis
Year 1 Year 5 Year 10 Year 20
Proctitis
5-ASA and/or rectal steroids 96 (92–98) 98 (94–99) 100 100
Corticosteroids (systemic) 45 (37–52) 48 (41–55) 64 (55–72) 64 (55–72)
Immunomodulators 18 (13–24) 36 (28–43) 36 (28–43) 44 (35–53)
TNF antagonists 8 (3–12) 8 (3–13) 19 (7–29) NA
Calcineurin inhibitors 0 10 (4–14) 10 (4–14) 10 (4–14)
Surgery 0 0 4 (0–7) 12 (4–20)
Left-sided colitis
5-ASA and/or rectal steroids 93 (90–95) 97 (94–99) 98 (96–99) 99 (96–100)
Corticosteroids (systemic) 62 (56–67) 68 (62–73) 74 (68–79) 77 (70–82)
Immunomodulators 44 (39–50) 59 (53–65) 62 (56–67) 68 (61–74)
TNF antagonists 16 (11–21) 31 (24–37) 41 (31–49) NA
Calcineurin inhibitors 5 (3–8) 8 (4–10) 11 (7–15) 11 (7–15)
Surgery 1 (0–1) 4 (2–6) 8 (4–11) 11 (5–15)
Extensive/pancolitis
5-ASA and/or rectal steroids 90 (86–93) 92 (89–94) 92 (89–94) 97 (93–99)
Corticosteroids (systemic) 71 (66–75) 79 (75–83) 79 (75–83) 86 (81–90)
Immunomodulators 53 (48–58) 64 (59–69) 67 (62–72) 69 (64–74)
TNF antagonists 19 (14–23) 35 (29–41) 38 (31–45) NA
Calcineurin inhibitors 6 (3–8) 12 (9–16) 12 (9–16) 14 (10–18)
Surgery 2 (1–3) 9 (6–12) 14 (10–18) 29 (21–36)
All locations
5-ASA and/or rectal steroids 91 (89–93) 96 (94–97) 96 (95–98) 97 (96–98)
Corticosteroids (systemic) 63 (59–65) 69 (66–72) 72 (69–75) 79 (75–82)
Immunomodulators 43 (40–46) 57 (54–60) 59 (55–62) 64 (60–67)
TNF antagonists 15 (12–17) 28 (24–32) 35 (30–40) NA
Calcineurin inhibitors 5 (4–6) 9 (7–11) 11 (9–13) 12 (10–15)
Surgery 1 (0–2) 5 (4–7) 9 (7–11) 18 (14–22)
The point estimates were calculated using Turnbull’s Extension to the Kaplan–Meier method (percentage and 95% conﬁdence interval in parentheses).
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TABLE 3. Univariate Logistic Regression Modeling to Identify Risk Factors Associated with Particular Therapies in
UC Patients
Outcome
At Least Corticosteroids At Least IM At Least TNF Antagonists
OR 95% CI P OR 95% CI P OR 95% CI P
Sex
Male 1 (ref) — — 1 (ref) — — 1 (ref) — —
Female 0.790 0.565–1.104 0.168 0.818 0.622–1.076 0.150 0.715 0.540–0.947 0.019
Age at diagnosis
#40 yr 1 (ref) — — 1 (ref) — — 1 (ref) — —
.40 yr 0.728 0.505–1.049 0.088 0.728 0.536–0.989 0.043 0.662 0.476–0.920 0.014
Smoker status at diagnosis
No 1 (ref) — — 1 (ref) — — 1 (ref) — —
Yes 0.840 0.537–1.315 0.446 1.030 0.704–1.507 0.878 0.753 0.503–1.126 0.167
IBD family history
Negative 1 (ref) — — 1 (ref) — — — — —
Positive 1.167 0.661–2.059 0.594 0.959 0.616–1.493 0.853 1.265 0.815–1.962 0.295
Presence of EIM from time of
enrollment until last
follow-up visit
No 1 (ref) — — — — — — — —
Yes 2.556 1.737–3.761 ,0.001 2.110 1.575–2.828 ,0.001 2.153 1.622–2.857 ,0.001
Location at time of diagnosis
Proctitis 1 (ref) — — — — — — — —
Left-sided 2.207 1.481–3.288 ,0.001 2.396 1.661–3.455 ,0.001 2.280 1.439–3.448 ,0.001
Pancolitis 6.064 3.813–9.642 ,0.001 3.768 2.608–5.445 ,0.001 3.301 2.162–5.039 ,0.001
Disease duration per years 1.021 0.999–1.043 0.057 0.998 0.982–1.015 ,0.001 0.990 0.974–1.007 0.245
Outcome
At Least Calcineurin Inhibitors At Least UC-related Surgery
OR 95% CI P OR 95% CI P
Sex
Male 1 (ref) — — 1 (ref) — —
Female 0.753 0.525–1.081 0.124 0.675 0.424–1.074 0.097
Age at diagnosis
#40 yr 1 (ref) — — 1 (ref) — —
.40 yr 0.803 0.528–1.223 0.306 1.011 0.606–1.685 0.976
Smoker status at diagnosis
No 1 (ref) — — 1 (ref) — —
Yes 0.681 0.394–1.175 0.168 0.336 0.133–0.851 0.021
IBD family history
Negative 1 (ref) — — 1 (ref) — —
Positive 1.379 0.811–2.346 0.235 1.877 1.023–3.445 0.042
Presence of EIM from time of
enrollment until last
follow-up visit
No 1 (ref) — — 1 (ref) — —
Yes 2.343 1.635–3.358 ,0.001 2.341 1.483–3.695 ,0.001
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The point estimates of the cumulative probability of
calcineurin inhibitor (cyclosporine, tacrolimus) use for all disease
locations together were as follows: 5% (95% CI, 4%–6%) at year
1 after diagnosis, 9% (95% CI, 7%–11%) at year 5 after diagnosis,
and 11% (95% CI, 9%–13%) at year 10 after diagnosis. To the
best of our knowledge, no data on the long-term follow-up of
patients with UC treated with calcineurin inhibitors in other co-
horts have been reported.
When all disease locations were examined together, the
point estimates of cumulative probability of proctocolectomy or
colectomy with ileorectal anastomosis were as follows: 1% (95%
CI, 0%–2%) at year 1 after diagnosis, 5% (95% CI, 4%–7%) at
year 5 after diagnosis, 9% (95% CI, 7%–11%) at year 10 after
diagnosis, and 18% (95% CI, 14%–22%) at year 20 after UC
diagnosis. As such, the annual rate of UC-related surgery
was roughly 1%. The surgery rate in our cohort during the ﬁrst
5 years of disease duration is comparable with the one reported by
Lakatos et al.18 Authors reported on a colectomy rate of 2.3% in
the incidence cohort of 220 patients with UC (over a median
follow-up time of 5 yr).18 Our results compare well with those
of other studies, in which a 25-year cumulative probability of
colectomy ranging between 20% and 30% was reported. It is
important to point out that higher point estimates of cumulative
probability for UC-related surgery have been reported in studies
conducted in referral centers when compared with population-
based studies.10,21–23
When we conducted the analysis to identify risk factors for
therapy escalation in UC, we found that EIM and extensive
disease at the time of diagnosis (left-sided colitis and extensive
colitis/pancolitis) were associated with an elevated risk for
undergoing treatment with at least corticosteroids and at least
immunomodulators. Furthermore, we found that EIM and exten-
sive disease at the time of diagnosis were also risk factors for
treatment with at least TNF antagonists, while female sex and age
.40 years at the time of UC diagnosis were protective. The
presence of EIM, extended disease location at the time of diag-
nosis (extensive colitis/pancolitis), and the disease duration were
identiﬁed as risk factors for (procto)-colectomy. Cigarette smok-
ing at UC diagnosis had a protective effect for undergoing UC-
related surgery. Our results are in accordance with ﬁndings of
a 10-year observational study, in which extensive colitis at the
time of UC diagnosis was signiﬁcantly associated with colectomy
during the follow-up period (hazard ratio ¼ 2.98, 95% CI, 1.25–
7.08, P ¼ 0.013), whereas cigarette smoking had a protective but
TABLE 3 (Continued )
Outcome
At Least Calcineurin Inhibitors At Least UC-related Surgery
OR 95% CI P OR 95% CI P
Location at diagnosis
Proctitis 1 (ref) — — 1 (ref) — —
Left-sided 1.467 0.821–2.620 0.196 1.464 0.632–3.393 0.374
Pancolitis 2.687 1.561–4.623 ,0.001 3.898 1.818–8.359 ,0.001
Disease duration per year 1.011 0.991–1.032 0.275 1.037 1.014–1.062 0.002
CI, conﬁdence interval; IM, immunomodulators (azathiopurine, 6-mercaptopurine, methotrexate); OR, odds ratio.
TABLE 4. Multivariate Logistic Regression Modeling of
the Factors with P value ,0.1 as Presented in Table 3
Outcome Odds Ratio 95% CI P
At least systemic steroids
Age at Dx .40 yr 0.759 0.511–1.127 0.172
Presence of EIM 2.393 1.603–3.573 ,0.001
Left-sided colitis 2.211 1.470–3.326 ,0.001
Extensive/pancolitis 5.806 3.627–9.295 ,0.001
Disease duration 1.013 0.990–1.036 0.270
At least immunomodulators
Age at Dx .40 yr 0.706 0.512–0.974 0.034
Presence of EIM 2.048 1.514–2.771 ,0.001
Left-sided colitis 2.422 1.667–3.520 ,0.001
Extensive/pancolitis 3.678 2.528–5.351 ,0.001
At least TNF antagonists
Female sex 0.723 0.537–0.973 0.032
Age at Dx .40 yr 0.607 0.429–0.856 0.004
Presence of EIM 2.145 1.603–2.872 ,0.001
Left-sided colitis 2.142 1.372–3.346 0.001
Extensive/pancolitis 2.903 1.881–4.481 ,0.001
At least colectomy
Female sex 0.647 0.378–1.109 0.113
Smoking at diagnosis 0.272 0.103–0.716 0.008
IBD family history 1.636 0.818–3.274 0.164
Presence of EIM 2.299 1.363–3.881 0.002
Left-sided colitis 1.737 0.705–4.278 0.230
Extensive/pancolitis 3.083 1.322–7.191 0.009
Disease duration 1.042 1.013–1.072 0.004
CI, conﬁdence interval; EIM, extraintestinal manifestations.
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insigniﬁcant effect on colectomy.24 To the best of our knowledge,
no other study has shown that the presence of EIM during the
disease course represents a risk factor for therapeutic step-up,
including colectomy.
Our article has several strengths. We present data on the
therapeutic escalation over time in a large and well-characterized
cohort of patients with UC. Such data are urgently needed given
the lack of comparable studies. In addition, the median duration of
the follow-up period for patients in this study is 9 years, which
means that our data are appropriate for evaluation of disease
outcome over time. In addition to validating already known risk
factors, such as disease extent, we discovered another important
risk factor, namely the presence of EIM, which represents a risk
factor for therapy escalation, including colectomy. However, the
ﬁndings of our study should be interpreted with a number of
considerations in mind. One important limitation of our study is
that the SIBDCS is not a population-based study. As such, our
results are subject to a referral center bias. Because 80% of
patients with UC in the SIBDCS were recruited in referral centers
and only 20% of patients by gastroenterologists in private
practice, patients with UC suffering from mild disease are
potentially underrepresented. Thus, the cumulative proportion of
patients with UC in need of a therapy escalation could be lower in
patients managed by primary care physicians. Therefore, the
presented data is more likely to be applicable to patients seen at
a Swiss referral center but not necessarily to a broader UC
population nor perhaps to the patients in practices in other
countries. In addition, given the fact that the presence of EIM
in our study was examined during the entire disease course, this
parameter does not necessarily represent a risk factor for therapy
escalation but may represent per se an indication for step-up
therapy.
In summary, we were able to characterize the requirement
for step-up therapy over time in a large well-characterized cohort
of patients with UC and to identify risk factors for such a therapy
escalation. These results will allow the treating gastroenterologists
to perform a risk assessment and to provide patients with the
estimates of their future therapy use.
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